Atlas Venture Life Science Advisors, LLC Long-Term Concentrated

Name: Atlas Venture Life Science Advisors, LLC Q1 2022 13F Filing | 13F Explorer
Creator: Atlas Venture Life Science Advisors, LLC
Published: 2022-05-16

Location: Cambridge, MA

CIK: 0001917529 · Show all filings

Period: Q1 2022 (← Previous) (Next →)

Filing Date: May 16, 2022

Total Value: $791M (100.0% shares, 0.0% debt)

Holdings (17)

KYMR Kymera Therapeutics, Inc. 36.8%

Value $291M Shares 6,875,698 Est. Cost $58.25 Unrealized -27.5%

DYN Dyne Therapeutics, Inc. 10.9%

Value $86.13M Shares 8,934,902 Est. Cost $14.05 Unrealized -39.4%

DAWN Day One Biopharmaceuticals, Inc. 10.3%

Value $81.36M Shares 8,201,638 Est. Cost $20.55 Unrealized -35.7%

— Generation Bio, Co. 7.7%

Value $60.77M Shares 8,278,876 Est. Cost $7.08 Unrealized —

— Aerovate Therapeutics, Inc. 7.2%

Value $56.89M Shares 3,103,879 Est. Cost $11.79 Unrealized —

REPL Replimune Group, Inc. 6.9%

Value $54.5M Shares 3,209,627 Est. Cost $29.91 Unrealized -36.9%

— Vigil Neuroscience, Inc. 5.2%

Value $41.03M Shares 5,836,874 Est. Cost $7.03 Unrealized —

— Akero Therapeutics, Inc. 4.0%

Value $31.68M Shares 2,232,251 Est. Cost $21.15 Unrealized —

— Ikena Oncology, Inc. 3.9%

Value $30.61M Shares 5,018,178 Est. Cost $12.54 Unrealized —

XLO Xilio Therapeutics, Inc. 2.5%

Value $19.51M Shares 2,759,344 Est. Cost $17.03 Unrealized -33.7%

— Magenta Therapeutics, Inc. 1.3%

Value $10.08M Shares 3,476,536 Est. Cost $4.43 Unrealized —

SPRO Spero Therapeutics, Inc. 1.1%

Value $8.971M Shares 1,031,160 Est. Cost $15.88 Unrealized -35.5%

— Gemini Therapeutics, Inc. 0.9%

Value $7.304M Shares 5,254,365 Est. Cost $2.91 Unrealized —

— AvroBio, Inc. 0.8%

Value $5.968M Shares 4,520,863 Est. Cost $3.85 Unrealized —

— F-star Therapeutics, Inc. 0.3%

Value $2.128M Shares 599,524 Est. Cost $5.02 Unrealized —

VRDN Viridian Therapeutics, Inc. 0.2%

Value $1.665M Shares 90,072 Est. Cost $18.63 Unrealized +3.2%

COGT Cogent Biosciences, Inc. 0.2%

Value $1.397M Shares 186,487 Est. Cost $8.69 Unrealized -19.9%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
KYMR	Kymera Therapeutics, Inc.	6,875,698	$291M	36.8%	$58.25	-27.5%	Common Stock	501575104
DYN	Dyne Therapeutics, Inc.	8,934,902	$86.13M	10.9%	$14.05	-39.4%	Common Stock	26818M108
DAWN	Day One Biopharmaceuticals, Inc.	8,201,638	$81.36M	10.3%	$20.55	-35.7%	Common Stock	23954D109
—	Generation Bio, Co.	8,278,876	$60.77M	7.7%	$7.08	—	Common Stock	37148K100
—	Aerovate Therapeutics, Inc.	3,103,879	$56.89M	7.2%	$11.79	—	Common Stock	008064107
REPL	Replimune Group, Inc.	3,209,627	$54.5M	6.9%	$29.91	-36.9%	Common Stock	76029N106
—	Vigil Neuroscience, Inc.	5,836,874	$41.03M	5.2%	$7.03	—	Common Stock	92673K108
—	Akero Therapeutics, Inc.	2,232,251	$31.68M	4.0%	$21.15	—	Common Stock	00973Y108
—	Ikena Oncology, Inc.	5,018,178	$30.61M	3.9%	$12.54	—	Common Stock	45175G108
XLO	Xilio Therapeutics, Inc.	2,759,344	$19.51M	2.5%	$17.03	-33.7%	Common Stock	98422T100
—	Magenta Therapeutics, Inc.	3,476,536	$10.08M	1.3%	$4.43	—	Common Stock	55910K108
SPRO	Spero Therapeutics, Inc.	1,031,160	$8.971M	1.1%	$15.88	-35.5%	Common Stock	84833T103
—	Gemini Therapeutics, Inc.	5,254,365	$7.304M	0.9%	$2.91	—	Common Stock	36870G105
—	AvroBio, Inc.	4,520,863	$5.968M	0.8%	$3.85	—	Common Stock	05455M100
—	F-star Therapeutics, Inc.	599,524	$2.128M	0.3%	$5.02	—	Common Stock	30315R107
VRDN	Viridian Therapeutics, Inc.	90,072	$1.665M	0.2%	$18.63	+3.2%	Common Stock	92790C104
COGT	Cogent Biosciences, Inc.	186,487	$1.397M	0.2%	$8.69	-19.9%	Common Stock	19240Q201